Could an Anti-Inflammatory pill help control diabetes?

NCT ID NCT06047262

Recruiting now Disease control Sponsor: Marc Donath Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests dapansutrile, an oral drug that reduces inflammation, in 300 adults with type 2 diabetes. The goal is to see if it improves blood sugar control and lowers the risk of diabetes-related complications. Participants are randomly assigned to receive either the drug or a placebo for comparison.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapansutrile (an oral anti-inflammatory drug)
What this could lead to: If successful, this could offer a new way to manage type 2 diabetes by reducing inflammation, potentially lowering blood sugar and risk of complications.
What could go wrong: This is an early Phase 2 trial with 300 people, so results are not yet proven. The drug may not improve blood sugar control or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

CHU de Liege
RECRUITING

Liège, 4000, Belgium
Deutsches Zentrum für Diabetesforschung Düsseldorf
RECRUITING

Düsseldorf, Nordrhein-Westphalen, 40225, Germany
Hopital Bichat
RECRUITING

Paris, Île-de-France Region, 75018, France
Hopital Lariboisiere
RECRUITING

Paris, Île-de-France Region, 75010, France
Kantonsspital Olten
RECRUITING

Olten, Canton of Solothurn, 4600, Switzerland
University Hospital Basel
TERMINATED

Basel, Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.